Multiple Myeloma

Multiple Myeloma

A collection of features and news articles published in ASH Clinical News related to multiple myeloma.

Examining Outcomes Among Hispanic Patients With Multiple Myeloma

Hispanic and non-Hispanic Black patients with multiple myeloma (MM) more often present with disease at a younger age and with significant renal dysfunction. These...
On location

Idecabtagene Vicleucel Promising in Pretreated Myeloma

Three-quarters of patients with heavily pretreated multiple myeloma responded to treatment with the B-cell maturation antigen (BCMA)−targeted chimeric antigen receptor (CAR) T-cell therapy idecabtagene...
On location

Evaluating Iberdomide Plus Daratumumab or Bortezomib in Relapsed/Refractory Myeloma

Triplet combinations consisting of iberdomide, a cereblon E3 ligase immunomodulatory drug, with dexamethasone and daratumumab (IberDd) or bortezomib and dexamethasone (IberVd) demonstrated favorable tolerability...
On location

Teclistamab Shows Promise for Myeloma in Phase I Trial

Approximately three-quarters of patients with relapsed and/or refractory multiple myeloma (MM) responded to treatment with the bispecific antibody teclistamab, according to results from a...

The Future of Chronic Graft-Versus-Host Disease

An Update From the 3rd NIH Chronic GVHD Consensus Conference In this edition, Steven Pavletic, MD, and Kirk Schultz, MD, report on the progress and...

BOSTON: Selinexor Improves Progression-Free Survival in Relapsed/Refractory Myeloma

The combination of once-weekly selinexor with bortezomib and dexamethasone (SVd) demonstrated a 30% reduction in the risk of disease progression or death, compared with...
On location

Examining Immune Response in Patients with Hematologic Malignancy After COVID-19 Infection

Patients with a history of a hematologic malignancy who survive COVID-19 infection have similar immune responses against the virus following infection compared with people...
On location

Phase III Trial Supports Efficacy of Subcutaneous Daratumumab in Relapsed/Refractory Myeloma

Patients with relapsed/refractory multiple myeloma (MM) who were treated with a combination of subcutaneous daratumumab plus pomalidomide-dexamethasone (Pd) had a 37% lower risk of...
On location

CARTITUDE-1: Myeloma CAR T-Cell Therapy Produces Deep and Durable Responses

A single low-dose infusion of ciltacabtagene autoleucel (cilta-cel), an autologous chimeric antigen receptor (CAR) T-cell therapy, was safe and associated with early, deep, and...

Large Meta-Analysis Confirms Predictive Value of MRD Negativity in Myeloma

Achievement of measurable residual disease (MRD) negativity is associated with significant improvements in progression-free survival (PFS) and overall survival (OS) in patients with multiple...

Current Issue

October 2021, Volume 7, Issue 12

This issue tells the long story of drug shortages, demystifies transfusion services, and more.

Block title